Prostate Cancer

Combo has potential to be new standard of care in patients with high-risk BCR, expert says

ODAC votes that olaparib-abiraterone combination should be restricted to BRCA-positive subset

Agency asking ODAC if olaparib-abiraterone should be reserved for BRCA-positive subset

All but one patient had a PSA decline after a fractionated dose of 225Ac-J591

PSA screening rates over 50% for men 70 and up, despite USPSTF recommendations against it

Consider "trade-offs" between harms and benefits of treatments, say researchers

Also in TTHealthWatch: low-risk prostate cancer in the U.S.

And rates still remain "suboptimal," argue researchers

Health news and commentary from around the Web gathered by MedPage Today staff

But add-on abiraterone and apalutamide may offer some benefits in those with higher PSA

Final PROpel analysis also shows trend toward overall survival improvement with PARP inhibitor

Combination achieved a 37% reduction in risk of progression, death versus ARPI alone

Benefit in selected patients seen over physician's choice of docetaxel or second-generation ARPI

Physicians must consider patient perspectives on the Gleason 6 debate